Aptorum Group Limited news
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--May 2, 2022-- Regulatory News:
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, is pleased to announce the finalized data from the Phase 1 clinical trial of SACT-1, a repurposed small molecule drug targeting Neuroblastoma and potentially other
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Apr. 22, 2022--
Regulatory News:
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company dedicated to meeting unmet medical needs in oncology and infectious diseases, today announced that an interview with President Mr. Darren Lui will
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Apr. 25, 2022-- Regulatory News:
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, is pleased to announce that the US Patent and Trademark Office (“US PTO”) has granted the patent regarding the Rapid Pathogen Infec
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Jan. 20, 2022-- Regulatory News:
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, is pleased to announce that the United States Food and Drug Administration (FDA) Office has granted Orphan Drug Designation to SACT-1, a repurpose
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Jan. 18, 2022-- Regulatory News:
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, is pleased to announce that the US Patent and Trademark Office has granted the first patent regarding Aptorum’s SACT-1 repurposed drug for the treatment of various cancers including but not limited to neuro
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Jan. 10, 2022-- Regulatory News:
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announces the launch of its oncology and autoimmune discovery and development platform with an initial focus on indications including, but not limited to, non-small cell lung cancer (“NSCLC”) and autoimmune dis
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Jan. 10, 2022-- Regulatory News:
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical-stage biopharmaceutical company, announces completion of the Phase I clinical trial for ALS-4 (a first in-class anti-virulence based small molecule drug targeting infections caused by Staphylococcus aureus, including, but not limited to Methicillin Resist
NEW YORK & LONDON & PARIS--(BUSINESS WIRE)--Sep. 15, 2021-- Regulatory News:
Aptorum Group Limited (Nasdaq: APM, Euronext Paris: APM) (“Aptorum Group” or “Aptorum”), a clinical stage biopharmaceutical company focused on novel technologies including the targeting of oncological diseases, announced that the group has received clearance from the US FDA regarding the IND application to initiate clinical trials of SACT-1, a